Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer
News | Prostate Cancer
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
Results show Black women had significantly higher rates of radiation therapy recommendation compared to White women with similar biosignature scores
News | Radiation Therapy
PreludeDx Presents Comparative Data Analyzing Racial/Ethnic Radiation Therapy Treatment Recommendation Changes using DCISionRT

May 1, 2023 — Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage ...

Time May 01, 2023
arrow
GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements
News | PET Imaging
GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

April 28, 2023 — GE HealthCare to deliver two Cyclotrons next year, expanding South Africa’s capacity to produce ...

Time April 28, 2023
arrow
NorthStar Medical Radioisotopes has expanded its management team with the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

April 24, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 24, 2023
arrow
NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

April 13, 2023 —NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 13, 2023
arrow
RaySearch Laboratories AB announced that the number of clinics in the world that have bought RayStation for treatment planning for ions (for example protons, carbon ions and helium ions) has surpassed 100
News | Proton Therapy
RayStation Selected by More Than 100 Ion Therapy Clinics Worldwide

April 5, 2023 — RaySearch Laboratories AB announced that the number of clinics in the world that have bought RayStation ...

Time April 05, 2023
arrow
New radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) provides powerhouse combination of capabilities and expertise to advance patient care
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

April 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 03, 2023
arrow
newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate the biological changes that cause chemotherapy-related cognitive impairment (CRCI), commonly known as chemo-brain
News | Molecular Imaging
Molecular Imaging Offers Insight Into Chemo-brain

March 29, 2023 — A newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate ...

Time March 29, 2023
arrow
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications
News | PET Imaging
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

March 29, 2023 — Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to ...

Time March 29, 2023
arrow
Getz Healthcare announced that it has partnered with Subtle Medical, a Menlo Park, CA-based healthcare technology company, to distribute the company's artificial intelligence (AI)-based software solutions for faster and safer medical imaging.
News | Artificial Intelligence
Subtle Medical Partners with Getz Healthcare to Improve Medical Imaging with AI-powered Technology

March 29, 2023 — In a partnership which aims to provide faster and safer medical imaging across Australia and New ...

Time March 29, 2023
arrow
A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in the field of nuclear medicine and molecular imaging
News | Molecular Imaging
JNM Explores Potential Applications for ChatGPT in Nuclear Medicine and Molecular Imaging

March 28, 2023 — A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an ...

Time March 28, 2023
arrow
Results from the ELUCIDATE Phase 3 Trial of CYTALUX (pafolacianine) injection for use of IMI for cancer in the lung have been published
News | Lung Imaging
On Target Laboratories Announces Publication in Journal of Thoracic and Cardiovascular Surgery Phase 3 ELUCIDATE Trial of CYTALUX (pafolacianine) Injection for Intraoperative Imaging of Lung Cancer

March 27, 2023 — On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative ...

Time March 27, 2023
arrow
News | PET Imaging
Nuclidium and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumors

March 23, 2023 — Nuclidium announced that the Neuroendocrine Tumors Research Foundation (NETRF) has selected the company ...

Time March 24, 2023
arrow
A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in the March issue of The Journal of Nuclear Medicine.
News | Nuclear Imaging
New Compact and Low-cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging

March 22, 2023 — A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very ...

Time March 22, 2023
arrow
Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical services, is pleased to announce that it has executed a Clinical Study/Research Agreement with Ochsner Clinic Foundation
News | PET-CT
Positron Corporation Enters into Agreement with Ochsner Clinic Foundation for Clinical Study of its New “Affinity PET-CT 4D” Device

March 21, 2023 — Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical ...

Time March 21, 2023
arrow
RYZ101 positioned to be the first approved Actinium-225 radiopharmaceutical therapy for the industry
News | Radiopharmaceuticals and Tracers
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

March 20, 2023 — RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against ...

Time March 20, 2023
arrow
A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients
News | Radiopharmaceuticals and Tracers
Pluvicto Supply Shortage Update: What SNMMI is Doing

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...

Time March 16, 2023
arrow
Researchers found evidence of heart muscle inflammation in a small number of patients with acute myocarditis after COVID-19 vaccination, but not in patients without acute myocarditis
News | Coronavirus (COVID-19)
Study Examines Heart Inflammation after COVID Vaccine

March 10, 2023 — Researchers found evidence of heart muscle inflammation in a small number of patients with acute ...

Time March 10, 2023
arrow
Reveal Pharmaceuticals doses first subjects in Phase 1 Clinical Trial of RVP‑001
News | Contrast Media
New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care

March 9, 2023 — Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate ...

Time March 09, 2023
arrow
100-foot crane lifting Rhodotron TTE-300 HE Electron Beam Accelerator at NorthStar Medical Radioisotope's new Ac-225 Production facility in Beloit, Wisconsin (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)

March 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 03, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now